Article
Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRAS G12C NSCLC.
Scientific reports - 25 May 2026
Giménez-Capitán Ana, Olmo-Gónzalez Daniel, Martínez-Pérez Elizabeth, Aguilar-Hernández Andrés, González-Cao María, Reyes Roxana, Moya Irene, Albarrán Víctor, Sullivan Ivana, Valarezo Joselyn, García Beatriz, Román Ruth, De Las Casas Clara Mayo, Molina-Vila Miguel Ángel, Rosell Rafael
Abstract excerpt
Advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations can be treated with selective inhibitors, however progression-free survival remains limited. Resistance has been associated with co-mutations in TP53, STK11, and KEAP1, persistent plasma KRAS G12C, and activation of the MRAS-SHOC2-PP1C pathway with downstream YAP1 signaling. We evaluated the expression of MRAS-SHOC2-PP1C and YAP1-related...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.